If You Invested $10,000 In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now?

Abbott Laboratories ABT, together with its subsidiaries, discovers, develops, manufactures and sells health care products worldwide.

It is set to report its Q4 2024 earnings on Jan. 22, 2025. Wall Street analysts expect the company to post an EPS of $1.33, up from $1.19 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $10.85 billion, up from $10.24 billion in the previous year.

Don’t Miss:

• This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, and you only need $100.
• Your biggest returns may not come from the stock market. Invest the way colleges, pension funds, and the 1% do.Benzinga Readers: Earn a 1% return boost on your first EquityMultiple investment when you sign up here (Accredited Investors Only)*.

If You Bought Abbott Laboratories Stock 10 Years Ago

The company's stock traded at approximately $43.69 per share 10 years ago. If you had invested $10,000, you could have bought roughly 229 shares. Currently, shares trade at $116.80, meaning your investment's value could have grown to $26,734 from stock price appreciation alone. However, Abbott Laboratories also paid dividends during these 10 years. 

Abbott Laboratories' dividend yield is currently 1.88%. Over the last 10 years, it has paid about $14.82 in dividends per share, which means you could have made $3,392 from dividends alone. 

Summing up $26,734 and $3,392, we end up with the final value of your investment, which is $30,126. This is how much you could have made if you had invested $10,000 in Abbott Laboratories stock 10 years ago. This means a total return of 201.26%. However, this figure is even lower than the S&P 500 total return for the same period, which was 231.51%.

Trending: These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends

What Could The Next 10 Years Bring? 

Abbott Laboratories has a consensus rating of "Buy" and a price target of $128.64 based on the ratings of 29 analysts, implying over a 10% upside from the current stock price. Check out this article by Benzinga for 15 analysts' insights on Abbott Laboratories stock.

On Oct. 16, the company announced Q3 2024 earnings, posting sales of $10.64 billion, up 4.9% year-over-year, beating the consensus of $10.55 billion, as reported by Benzinga. 

Organic sales growth for the base business was 8.2%, led by double-digit growth in Medical Devices. Abbott's adjusted diluted EPS was $1.21, beating analyst estimates of $1.20.

Trending: Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

The company projects full-year 2024 adjusted EPS of $4.64-$4.70 versus prior guidance of $4.61-$4.71 and consensus of $4.66.

Abbott forecasts that in the fourth quarter of 2024, the adjusted EPS will be $1.31-$1.37 versus the consensus of $1.20.

Given the expected upside potential of 10%, growth-focused investors may find Abbott Laboratories stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 1.88% and consistent hikes. Abbott Laboratories has raised its dividend consecutively for the last 11 years.

Better Yields Than Some REITs?

The current interest rate environment has created an incredible opportunity for income-seeking investors to earn massive yields, but not through publicly-traded REITs.

Arrived Homes, the Jeff Bezos-backed investment platform, has launched its Private Credit Fund, which provides access to a pool of short-term loans backed by residential real estate with a target 7% to 9% net annual yield paid to investors monthly. It paid 8.1% in August. The best part? Due to high demand the maximum investment amount is currently $5,000 with a minimum investment of ONLY $100.

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.